June 23, 2022

The Honorable Xavier Becerra  
Secretary  
Department of Health and Human Services  
200 Independent Avenue, S.W.  
Washington, D.C. 20201

Dear Secretary Becerra:

We write to you today to urge you to utilize administrative authorities, including government patent use compulsory licensing under 28 U.S.C. 1498 and march-in and royalty-free rights under the Bayh-Dole Act, to lower prescription drug prices.

Americans pay more than two-and-a-half times as much for prescription drugs as people in other countries.\(^1\) This is especially perverse and upsetting, given that U.S. taxpayers drive biomedical research through more than $40 billion in annual investments through the National Institutes of Health.\(^2\) High U.S. medicine prices are the result of prescription drug corporations using their monopoly power to hike prices and pad their bottom lines. Meanwhile, U.S. law forbids direct government negotiations and other restrictions on pharmaceutical pricing.\(^3\) This uniquely American combination of rules has led to pharmaceutical companies making more money in the U.S. than the rest of the world combined for the 20 top-selling drugs.\(^4\)

Sky-high prices for medicines can be devastating for Americans’ finances and health, leading to hardships and personal tragedies for families across the nation.

One in four Americans report they have been unable to afford their medicines, with Black and brown communities disproportionately bearing this suffering.\(^5\) Patients confronted with exorbitant prices are forced to make difficult decisions between filling prescriptions and putting food on the table or paying rent. And people with chronic illnesses who are forced to skip or

---

delay medication due to cost are more likely to experience adverse health events, including death.\(^6\)

We thank you and President Biden for your leadership in seeking relief for many of these patients by calling for Congress to finally allow Medicare to negotiate drug prices for a selection of high-priced, brand-name drugs and to prevent prices for all drugs from rising faster than the rate of inflation.\(^7\) We stand committed to delivering on these vital legislative priorities. But to provide the urgent relief that Americans demand, including patients who would not initially benefit from Medicare drug price negotiations, you must simultaneously use the executive tools readily at your disposal.

Exercising these authorities would be extraordinarily popular – about 80 percent of voters favor breaking patent monopolies to reduce drug prices.\(^8\) Moreover, using executive tools to lower drug prices while also supporting robust drug pricing legislation is the policy of the administration as expressed by President Biden in the executive order he signed last summer, *Promoting Competition in the American Economy*.\(^9\) The order directs the Department of Health and Human Services to ensure that the patent system does not “unjustifiably delay generic drug and biosimilar competition,” while also expressing support for “aggressive” legislative reforms.\(^10\)

It also directs the National Institute of Standards and Technology to consider not finalizing a Trump-era regulation that would prevent the government from exercising certain rights under the *Bayh-Dole Act* to lower drug prices on medicines invented with taxpayer funds.\(^11\)

Utilizing patent licensing authorities under these statutes could introduce generic or biosimilar competition and dramatic price relief in a matter of months. In your report released in September 2021, you recognized that the federal government holds government use patent licensing rights under 28 U.S.C. 1498 and march-in rights under the *Bayh-Dole Act*.\(^12\) The report concludes that legislative and administrative actions presented in its pages “…will protect American patients and improve their access and adherence to medications by lowering drug prices through increased competition throughout the health care system.”\(^13\)

---


\(^10\) Id.

\(^11\) Id.


\(^13\) Id.
You personally understand the value that these authorities can provide to American patients. We appreciate that as California’s attorney general, you led a bipartisan initiative of state attorneys general in urging the prior administration to use its licensing authorities to ensure access to and secure a fair price for the drug remdesivir. As a member of Congress, you also called on the Obama administration to use competitive licensing to lower drug prices.

Now, you have the power to take on the monopoly abuses of the pharmaceutical industry and the responsibility to ensure Americans have affordable access to the medicines they need. We respectfully request a meeting with you by July 15, 2022 to discuss the Department’s efforts to urgently lower drug prices for Americans using these authorities. You can provide immediate relief for millions of patients from Big Pharma’s price gouging and show millions more Americans that you, President Biden, and his administration are on their side. Please do so without delay.

Sincerely,

Elizabeth Warren  
United States Senator

Lloyd Doggett  
Member of Congress

Angus S. King, Jr.  
United States Senator

Joaquin Castro  
Member of Congress

---


Sara Jacobs  
Member of Congress

Tammy Baldwin  
United States Senator

Cory A. Booker  
United States Senator

Jeffrey A. Merkley  
United States Senator

Jan Schakowsky  
Member of Congress

Katie Porter  
Member of Congress

Sherrod Brown  
United States Senator

Edward J. Markey  
United States Senator

Bernard Sanders  
United States Senator

James P. McGovern  
Member of Congress
Rosa L. DeLauro  
Member of Congress

Jesús G. "Chuy" García  
Member of Congress

Eleanor Holmes Norton  
Member of Congress

Sheila Jackson Lee  
Member of Congress

Ilhan Omar  
Member of Congress

Maxine Waters  
Member of Congress

Ritchie Torres  
Member of Congress

Andy Levin  
Member of Congress

Brenda L. Lawrence  
Member of Congress

Adriano Espaillat  
Member of Congress
Judy Chu
Member of Congress

Mark Pocan
Member of Congress

Ro Khanna
Member of Congress

Grace Meng
Member of Congress

Danny K. Davis
Member of Congress

Mondaire Jones
Member of Congress

Raúl M. Grijalva
Member of Congress

Michael F. Q. San Nicolas
Member of Congress

Pramila Jayapal
Member of Congress

Adam B. Schiff
Member of Congress
John Garamendi  
Member of Congress

Rashida Tlaib  
Member of Congress

Al Green  
Member of Congress

Carolyn B. Maloney  
Member of Congress

Nydia M. Velázquez  
Member of Congress

Ann McLane Kuster  
Member of Congress

Peter Welch  
Member of Congress

Frederica S. Wilson  
Member of Congress

David N. Cicilline  
Member of Congress

Nanette Diaz Barragán  
Member of Congress
Matt Cartwright  
Member of Congress

Sanford D. Bishop, Jr.  
Member of Congress

Jamaal Bowman, Ed.D.  
Member of Congress

Jamie Raskin  
Member of Congress

Veronica Escobar  
Member of Congress

Cori Bush  
Member of Congress

Jerrold Nadler  
Member of Congress

Jahana Hayes  
Member of Congress

Marie Newman  
Member of Congress

Karen Bass  
Member of Congress
Al Lawson
Member of Congress

Salud Carbajal
Member of Congress

Betty McCollum
Member of Congress

Melanie A. Stansbury
Member of Congress

Alan Lowenthal
Member of Congress

Lois Frankel
Member of Congress

Steve Cohen
Member of Congress

Terri A. Sewell
Member of Congress

Troy Carter
Member of Congress

Dean Phillips
Member of Congress
Yvette D. Clarke
Member of Congress

Dina Titus
Member of Congress

Alexandria Ocasio-Cortez
Member of Congress

Sheila Cherfilus-McCormick
Member of Congress

Grace F. Napolitano
Member of Congress

Norma J. Torres
Member of Congress

Alma S. Adams, Ph.D.
Member of Congress

Teresa Leger Fernández
Member of Congress

Anthony G. Brown
Member of Congress

Emanuel Cleaver, II
Member of Congress
Sean Casten
Member of Congress

Mary Gay Scanlon
Member of Congress

Bobby L. Rush
Member of Congress

Debbie Wasserman Schultz
Member of Congress

Marcy Kaptur
Member of Congress

Ed Perlmutter
Member of Congress